drugset / Trial / NCT03119012
P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aimed to compare the efficacy and safety of P2Y12 inhibitor monotherapy versus extended dual antiplatelet therapy (DAPT) following 12-month of DAPT in patients undergoing percutaneous coronary intervention (PCI) with bioresorbable scaffold (BRS)
Timeline
- Start
- 2017-04-19
- Primary completion
- 2017-12-18
- Completion
- 2018-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aspirin | Small molecule | 100 mg | — |
| Comparator | Clopidogrel | Small molecule | 75 mg | — |
| Comparator | Ticagrelor | Small molecule | 60 mg | — |